Novelion Therapeutics Inc. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/eba7f218-76a7-4b49-bb93-eb0d7f4270f3/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2018 | $-50.1M | 2018-01-01 – 2018-12-31 | evidence 0000827809-19-000005 |
| FY 2017 | $-86.8M | 2017-01-01 – 2017-12-31 | evidence 0000827809-18-000006 |
| FY 2016 | $-36.7M | 2016-01-01 – 2016-12-31 | evidence 0000827809-17-000012 |
| FY 2015 | $-23.3M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-478534 |
| FY 2014 | $-3.8M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-065836 |
| FY 2013 | $-28.5M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-076512 |
| FY 2012 | $-54.7M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-069517 |
| FY 2011 | $-41.4M | 2011-01-01 – 2011-12-31 | evidence 0001193125-13-069517 |
| FY 2010 | $-26.4M | 2010-01-01 – 2010-12-31 | evidence 0001193125-13-069517 |
| FY 2009 | $-54.3M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-075603 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Novelion Therapeutics Inc. — all facts · Revenue · Net Income